Quality Considerations for Recombinant DNA-Derived Biological Therapeutic Products: A Control Perspective on Cytokines

ISSN： 1173-8804

Source： BioDrugs, Vol.11, Iss.6, 1999-06, pp. : 367-376

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Practical Considerations in Converting from Plasma-Derived to Recombinant Hepatitis B Vaccines

By Lee I. Lee C-Y.

BioDrugs, Vol. 10, Iss. 1, 1998-07 ,pp. : 11-25

Adis International

Access to resources Recommend Favorite

Cytokines as Therapeutic Targets for Osteoarthritis

By Malemud C.J.

BioDrugs, Vol. 18, Iss. 1, 2004-01 ,pp. : 23-35

Adis International

Access to resources Recommend Favorite

Recombinant Relaxin: A Review of Pharmacology and Potential Therapeutic Use

By Gavino E.S. Furst D.E.

BioDrugs, Vol. 15, Iss. 9, 2001-09 ,pp. : 609-614

Adis International

Access to resources Recommend Favorite

Recombinant Antibodies as Therapeutic Agents: Pathways for Modeling New Biodrugs

By Frederico Aires da Silva Corte-Real Sofia Goncalves Joao

BioDrugs, Vol. 22, Iss. 5, 2008-01 ,pp. : 301-314

Adis International

Access to resources Recommend Favorite

Recombinant Drug Development, Regulation, and Commercialization: An Indian Industry Perspective

By Sahoo Niharika Manchikanti Padmavati

BioDrugs, Vol. 25, Iss. 2, 2011-04 ,pp. : 105-113

Adis International

Access to resources Recommend Favorite